GeNeuro SA financials
GeNeuro SA
213800FUJCKXO9LK3444 | Line item | 2023 | 2022 |
|---|---|---|
| Income statement | ||
| Operating profit (EBIT) | -€14.4M | -€11.2M |
| Net finance income / (cost) | -€395.5K | -€968.5K |
| Finance costs | €952.6K | €858.5K |
| Profit before tax | -€14.8M | -€12.2M |
| Income tax expense | €4.2K | €2.1K |
| Profit for the year | -€14.8M | -€12.2M |
| Total comprehensive income | -€15.5M | -€11.2M |
| Per share | ||
| Basic EPS | €-0.59 | €-0.51 |
| Diluted EPS | €-0.59 | €-0.51 |
| Free cash flow / share | €-0.41 | €-0.55 |
| Cash flow statement | ||
| Net cash from operating activities | -€10.1M | -€13.1M |
| Net cash from investing activities | €50.8K | -€49.9K |
| Purchase of PP&E (capex) | €12.5K | €57.4K |
| Purchase of intangibles | €12.5K | €0 |
| Net cash from financing activities | €6.3M | €13.1M |
| Lease liability payments | €238.8K | €214.4K |
| Balance sheet | ||
| Total assets | €6.4M | €11.5M |
| Non-current assets | €4.0M | €2.4M |
| Property, plant & equipment | €742.1K | €992.9K |
| Current assets | €2.3M | €9.1M |
| Cash & equivalents | €1.8M | €5.6M |
| Total equity | -€13.8M | €1.5M |
| — attributable to owners | -€13.8M | €1.5M |
| Non-current liabilities | €13.9M | €6.7M |
| Current liabilities | €6.2M | €3.3M |
| Derived metrics | ||
| Free cash flow | -€10.2M | -€13.1M |
| Return on equity | 107.1% | -833.5% |
| Cash conversion ratio | 0.69× | 1.07× |
| Capex coverage | -811.76× | -227.55× |
| Other reported items | ||
| Accumulated Other Comprehensive Income | -€100.0K | €628.7K |
| Additional Paidin Capital | €33.6K | €27.2M |
| Adjustments For Amortisation Expense | €0 | €2.4K |
| Adjustments For Decrease Increase In Loans and Advances To Banks | -€700 | €100 |
| Adjustments For Decrease Increase In Trade and Other Receivables | -€1.9M | €0 |
| Adjustments For Depreciation Expense | €293.8K | €286.0K |
| Adjustments For Finance Income Cost | -€86.6K | -€74.5K |
| Adjustments For Increase Decrease In Employee Benefit Liabilities | €131.6K | €49.6K |
| Adjustments For Increase Decrease In Other Current Liabilities | €1.4M | €168.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | €1.8M | €160.5K |
| Adjustments For Sharebased Payments | €245.4K | €824.4K |
| Cash Repayments of Advances and Loans From Related Parties | €0 | €12.5K |
| Current Financial Liabilities | €747.3K | €601.8K |
| Donations and Subsidies Expense | -€405.0K | -€452.2K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €7.1K | €126.4K |
| Equity and Liabilities | €6.4M | €11.5M |
| Finance Income | €75.9K | €7.6K |
| Gains Losses On Change In Fair Value of Derivatives | €806.9K | €0 |
| General and Administrative Expense | €3.0M | €3.2M |
| Income Taxes Paid Refund Classified As Operating Activities | €0 | €0 |
| Increase Decrease In Cash and Cash Equivalents | -€3.8M | -€12.6K |
| Increase Decrease In Credit Derivative Nominal Amount | — | €0 |
| Increase Decrease In Number of Shares Outstanding | — | 2.7M |
| Increase Decrease Through Sharebased Payment Transactions | €245.4K | €824.4K |
| Increase Decrease Through Transfer Between Revaluation Reserve and Retained Earnings | €0 | — |
| Increase Decrease Through Transfer To Statutory Reserve | €0 | — |
| Increase Decrease Through Treasury Share Transactions | -€1.4K | -€68.2K |
| Intangible Assets Other Than Goodwill | €1.2M | €1.1M |
| Interest Paid Classified As Financing Activities | €34.8K | €18.6K |
| Interest Received Classified As Investing Activities | €75.8K | €7.5K |
| Issue of Equity | — | €7.7M |
| Issued Capital | €1.1M | €1.1M |
| Net Foreign Exchange Gain | -€325.7K | -€117.6K |
| Noncurrent Derivative Financial Liabilities | €299.4K | €0 |
| Noncurrent Financial Assets | €260.8K | €249.5K |
| Noncurrent Financial Liabilities | €12.6M | €6.5M |
| Noncurrent Provisions For Employee Benefits | €928.3K | €153.8K |
| Noncurrent Receivables | €1.9M | €0 |
| Number of Shares Outstanding | 25.0M | 25.0M |
| Other Comprehensive Income | -€728.7K | €1.0M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | €0 | €0 |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | -€728.7K | €1.0M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | €0 | €0 |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | -€728.7K | €1.0M |
| Other Current Assets | €507.0K | €3.5M |
| Other Current Liabilities | €3.0M | €1.9M |
| Other Noncurrent Liabilities | €42.6K | €26.0K |
| Other Reserves | €42.8M | €42.8M |
| Payments For Share Issue Costs | €0 | €618.3K |
| Proceeds From Current Borrowings | €6.9M | €6.5M |
| Proceeds From Issuing Shares | €0 | €7.7M |
| Repayments of Current Borrowings | €328.2K | €160.4K |
| Research and Development Expense | €12.5M | €9.8M |
| Reserve of Exchange Differences On Translation | €202.2K | €202.2K |
| Retained Earnings Excluding Profit Loss For Reporting Period | -€42.2M | -€57.4M |
| Retained Earnings Profit Loss For Reporting Period | -€14.8M | -€12.2M |
| Revenue From Government Grants | €1.1M | €1.8M |
| Share Issue Related Cost | — | €618.3K |
| Trade and Other Current Payables To Trade Suppliers | €2.5M | €764.8K |
| Treasury Shares | €796.1K | €794.7K |
Every line item above is a fact tagged in GeNeuro SA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.